vs

Side-by-side financial comparison of Forge Global Holdings, Inc. (FRGE) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Forge Global Holdings, Inc. is the larger business by last-quarter revenue ($21.3M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). Forge Global Holdings, Inc. runs the higher net margin — -85.7% vs -177.4%, a 91.7% gap on every dollar of revenue. On growth, Forge Global Holdings, Inc. posted the faster year-over-year revenue change (10.6% vs -11.5%). Forge Global Holdings, Inc. produced more free cash flow last quarter ($-11.4M vs $-23.1M). Over the past eight quarters, Forge Global Holdings, Inc.'s revenue compounded faster (5.6% CAGR vs -12.2%).

Bharat Forge Limited is an Indian multinational company involved in forging, automotives, energy, construction and mining, railways, marine, aerospace and defence industries.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FRGE vs LAB — Head-to-Head

Bigger by revenue
FRGE
FRGE
1.1× larger
FRGE
$21.3M
$19.6M
LAB
Growing faster (revenue YoY)
FRGE
FRGE
+22.1% gap
FRGE
10.6%
-11.5%
LAB
Higher net margin
FRGE
FRGE
91.7% more per $
FRGE
-85.7%
-177.4%
LAB
More free cash flow
FRGE
FRGE
$11.7M more FCF
FRGE
$-11.4M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FRGE
FRGE
Annualised
FRGE
5.6%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
FRGE
FRGE
LAB
LAB
Revenue
$21.3M
$19.6M
Net Profit
$-18.2M
$-34.7M
Gross Margin
98.6%
48.5%
Operating Margin
-96.7%
-168.5%
Net Margin
-85.7%
-177.4%
Revenue YoY
10.6%
-11.5%
Net Profit YoY
0.6%
-28.8%
EPS (diluted)
$-1.37
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRGE
FRGE
LAB
LAB
Q3 25
$21.3M
$19.6M
Q2 25
$27.7M
$21.8M
Q1 25
$25.3M
$40.8M
Q4 24
$18.6M
Q3 24
$19.2M
$22.1M
Q2 24
$22.3M
$22.5M
Q1 24
$19.2M
$45.5M
Q4 23
$19.1M
$28.2M
Net Profit
FRGE
FRGE
LAB
LAB
Q3 25
$-18.2M
$-34.7M
Q2 25
$-12.6M
$-33.5M
Q1 25
$-16.2M
$-26.0M
Q4 24
$-15.6M
Q3 24
$-18.3M
$-26.9M
Q2 24
$-13.7M
$-45.7M
Q1 24
$-18.6M
$-32.2M
Q4 23
$-25.8M
$-19.8M
Gross Margin
FRGE
FRGE
LAB
LAB
Q3 25
98.6%
48.5%
Q2 25
99.4%
48.8%
Q1 25
99.2%
48.4%
Q4 24
98.3%
Q3 24
99.6%
54.9%
Q2 24
98.9%
46.1%
Q1 24
99.8%
53.1%
Q4 23
99.1%
47.6%
Operating Margin
FRGE
FRGE
LAB
LAB
Q3 25
-96.7%
-168.5%
Q2 25
-46.3%
-118.1%
Q1 25
-65.1%
-80.8%
Q4 24
-100.6%
Q3 24
-108.8%
-120.9%
Q2 24
-79.2%
-134.5%
Q1 24
-130.0%
-132.2%
Q4 23
-128.1%
-75.9%
Net Margin
FRGE
FRGE
LAB
LAB
Q3 25
-85.7%
-177.4%
Q2 25
-45.4%
-153.7%
Q1 25
-63.9%
-63.8%
Q4 24
-84.2%
Q3 24
-95.5%
-122.0%
Q2 24
-61.6%
-203.3%
Q1 24
-96.8%
-70.6%
Q4 23
-135.3%
-70.2%
EPS (diluted)
FRGE
FRGE
LAB
LAB
Q3 25
$-1.37
$-0.09
Q2 25
$-1.01
$-0.09
Q1 25
$-1.29
$-0.07
Q4 24
$3.81
Q3 24
$-1.49
$-0.07
Q2 24
$-1.13
$-0.12
Q1 24
$-1.55
$-0.27
Q4 23
$-0.15
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRGE
FRGE
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$60.7M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$202.6M
$399.7M
Total Assets
$252.0M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRGE
FRGE
LAB
LAB
Q3 25
$60.7M
$129.4M
Q2 25
$80.7M
$158.6M
Q1 25
$92.0M
$150.9M
Q4 24
$105.1M
Q3 24
$114.5M
$210.6M
Q2 24
$120.5M
$269.8M
Q1 24
$129.6M
$287.1M
Q4 23
$144.7M
$51.7M
Total Debt
FRGE
FRGE
LAB
LAB
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Stockholders' Equity
FRGE
FRGE
LAB
LAB
Q3 25
$202.6M
$399.7M
Q2 25
$200.5M
$424.5M
Q1 25
$213.5M
$454.6M
Q4 24
$223.6M
Q3 24
$234.5M
$489.3M
Q2 24
$245.4M
$510.3M
Q1 24
$252.2M
$577.3M
Q4 23
$263.5M
$-148.1M
Total Assets
FRGE
FRGE
LAB
LAB
Q3 25
$252.0M
$539.6M
Q2 25
$242.8M
$557.0M
Q1 25
$249.5M
$579.6M
Q4 24
$263.5M
Q3 24
$276.6M
$681.5M
Q2 24
$285.7M
$708.7M
Q1 24
$298.7M
$777.7M
Q4 23
$310.7M
$323.1M
Debt / Equity
FRGE
FRGE
LAB
LAB
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRGE
FRGE
LAB
LAB
Operating Cash FlowLast quarter
$-11.4M
$-22.2M
Free Cash FlowOCF − Capex
$-11.4M
$-23.1M
FCF MarginFCF / Revenue
-53.6%
-118.1%
Capex IntensityCapex / Revenue
0.2%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-73.5M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRGE
FRGE
LAB
LAB
Q3 25
$-11.4M
$-22.2M
Q2 25
$-7.8M
$-20.7M
Q1 25
$-12.8M
$-30.3M
Q4 24
$-40.5M
Q3 24
$-5.8M
$-27.9M
Q2 24
$-14.4M
$-39.0M
Q1 24
$-12.4M
$-62.5M
Q4 23
$-6.6M
$-14.1M
Free Cash Flow
FRGE
FRGE
LAB
LAB
Q3 25
$-11.4M
$-23.1M
Q2 25
$-7.9M
$-22.6M
Q1 25
$-12.9M
$-35.3M
Q4 24
$-41.3M
Q3 24
$-6.0M
$-30.1M
Q2 24
$-14.7M
$-41.0M
Q1 24
$-12.8M
$-63.3M
Q4 23
$-7.0M
$-14.1M
FCF Margin
FRGE
FRGE
LAB
LAB
Q3 25
-53.6%
-118.1%
Q2 25
-28.4%
-103.6%
Q1 25
-50.9%
-86.6%
Q4 24
-222.3%
Q3 24
-31.0%
-136.4%
Q2 24
-66.0%
-182.2%
Q1 24
-66.4%
-138.9%
Q4 23
-36.7%
-50.2%
Capex Intensity
FRGE
FRGE
LAB
LAB
Q3 25
0.2%
4.5%
Q2 25
0.4%
8.7%
Q1 25
0.2%
12.4%
Q4 24
4.3%
Q3 24
0.7%
10.2%
Q2 24
1.2%
8.6%
Q1 24
2.1%
1.7%
Q4 23
2.2%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRGE
FRGE

Marketplace$12.2M57%
Custodial Administration Fees$9.1M43%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons